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ABSTRACT
Specific control of gene activity is a valuable tool to
study and engineer cellular functions. Recent
studies uncovered the potential of transcription
activator-like effector (TALE) proteins that can be
tailored to activate user-defined target genes. It
remains however unclear whether and how epigen-
etic modifications interfere with TALE-mediated
transcriptional activation. We studied the activity
of five designer TALEs (dTALEs) targeting the oct4
pluripotency gene. In vitro assays showed that the
five dTALEs that target distinct sites in the oct4
promoter had the expected DNA specificity
and comparable affinities to their corresponding
DNA targets. In contrast to their similar in vitro
properties, transcriptional activation of oct4 by
these distinct dTALEs varied up to 25-fold. While
dTALEs efficiently upregulated transcription of the
active oct4 promoter in embryonic stem cells (ESCs)
they failed to activate the silenced oct4 promoter in
ESC-derived neural stem cells (NSCs), indicating
that as for endogenous transcription factors also
dTALE activity is limited by repressive epigenetic
mechanisms. We therefore targeted the activity of
epigenetic modulators and found that chemical in-
hibition of histone deacetylases by valproic acid or
DNA methyltransferases by 5-aza-20-deoxycytidine
facilitated dTALE-mediated activation of the
epigenetically silenced oct4 promoter in NSCs.
Notably, demethylation of the oct4 promoter
occurred only if chemical inhibitors and dTALEs
were applied together but not upon treatment with
inhibitors or dTALEs only. These results show that
dTALEs in combination with chemical manipulation
of epigenetic modifiers facilitate targeted transcrip-
tional activation of epigenetically silenced target
genes.
INTRODUCTION
The ability to speciﬁcally manipulate the expression of
endogenous genes by engineered designer transcription
factors has wide-ranging applications in basic and
applied biology (1–4). Availability of suitable DNA-
binding scaffolds that can be tailored to bind user-deﬁned
target sequences has been the major limitation in the gen-
eration and application of designer transcription factors.
Recent studies however demonstrated that transcription
activator-like effector proteins (TALEs) from the plant
pathogenic bacterial genus Xanthomonas contain a
DNA-binding domain that can be adjusted to bind any
desired target sequence with high speciﬁcity (5–9). The
TALE DNA-binding domain is composed of tandem
arranged 33–35 amino acid repeats, with each repeat
binding to one base (10,11). Base preferences of repeats
are speciﬁed by residues 12 and 13, known as the repeat
variable diresidues (RVDs), that determine preferential
pairing with A (NI), C (HD), G (NK) and T (NG) nu-
cleotides, respectively. The use of this TALE code facili-
tates the assembly of TALE repeat arrays that bind any
desired DNA sequence (12).
A recent study investigated a large number of dTALEs
and found that most, but not all, activated the desired tar-
get promoters (5). Notably, the epigenetically controlled
oct4 and c-myc gene could not be upregulated by their
matching dTALEs, suggesting that epigenetic modiﬁca-
tions affect dTALE-mediated gene activation.
We systematically investigated the application of
dTALEs to the murine pluripotency gene oct4 to clarify
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The inspection of ﬁve dTALEs that bind to distinct
DNA sequences within the oct4 promoter revealed
similar afﬁnities to their DNA targets but up to 25-fold
differences in their efﬁciency as transcriptional activators.
Further studies revealed that dTALE-mediated activation
of a silent oct4 promoter in neural stem cells (NSCs) can
be drastically improved by treatment with the his-
tone deacetylase (HDAC) inhibitor valproic acid (VPA)
and the DNA methyltransferase inhibitor 5-aza-20-
deoxycytidine (5azadC). These data suggest that
chromatin modiﬁcations that are involved in
transcriptional gene silencing, hinder dTALE-mediated
gene activation and that simultaneous inhibition of
HDACs and DNA methyltransferases may overcome
this limitation of dTALE technology.
MATERIALS AND METHODS
Construction of plasmids
A Gateway cassette from pGWB5 (13) was ampliﬁed
(forward primer: 50-GGGGCGATCGCACAAGTTTGT
ACAAAAAAGCTGAACGAG-30; reverse primer: 50-G
GGGCGGCCGCAACCACTTTGTACAAGAAAGCT
GAACG-30), thereby adding AsiSI and NotI restriction
sites. This fragment was cloned via AsiSI and NotI into
pCAG_mCh (14) generating pCAG_mCh_GW. The
VP16AD was ampliﬁed from RSV
E2F1-VP16 (15) (forward primer: 50GGGGGTCTCT
CACCATGGATCCTGCCCCCCCGACCGATGTCAG
C-30; reverse primer:50-GGGGGTCTCCCTTCTACCCA
CCGTACTCGTCAATTCCAAGG-30), thereby adding a
BamHI restriction site to the 50 end and cloned into
pENTR-D- TOPO (Invitrogen) generating pENTR-D-
BamHI_VP16AD. TALE repeat arrays were generated
via multi-fragment cut-ligation using golden gate cloning
(16) and ligated either into pENTR-D-TALE-rep-BpiI-
A or pENTR-D-TALE-rep-BpiI-AC-VP16AD. All
entry clones were transferred by LR recombination
(Invitrogen) into the expression vector pCAG_mCh_GW.
The oct4 reporter construct (poct4-GFP) was generated
by inserting the XhoI/AvrII fragment of GOF-18 (17)
which includes the basepairs  1t o 4716 upstream of
the transcriptional start site of oct4 together with a
linker oligo (50-CCTAGGTGAGCCGTCTTTCCACCA
GGCCCCCGGCTCGGGGTGCGATCGCCGCCCAT
GG-30) into pGL-3 basic (Promega) cut with XhoI/NcoI.
Subsequently, the Luciferase ORF was removed by
cutting with KasI/FseI and the eGFP ORF (ampliﬁed
with: forward primer: 50-AAAGGCGCCAGTGAGCAA
GGGCG-30; reverse primer: 50-AAAGGCCGGCCTTAC
TTGTACAGCTCGTCC-30) was inserted.
The promoter mutants TB83, TB68, TB60 and TB31
were generated by site-directed mutagenesis using a
AsiSI/AatII derived sub-cloned poct4-GFP fragment as
template with either forward primer: 50-TCTCCCACCC
CCACAGCTCTGCTCCTTTGGGGAGGGAGAGGT
GAAAC-30,5 0-GCTCTGCTCCTCCACCCACCCAGG
GGTTGGGGAGGGAGAGGTGAAACCG-30,00 50-CC
TCCACCCACCCAGGGGGCGGGGCCTTGGGGAG
GGAGAGGTGAAACCG-30 or 50-GGTCAAGGCTAG
AGGGTGGGATTGGGTTGGGGAGGGAGAGGTG
AAACCG-30 together with reverse primer: 50-GAAACTG
AGGCGAGCGCTATCTG-30, thereby deleting TB83,
TB68; TB60 and TB31 and inserting them individually
at the position of TB31.
Immunoﬂuorescence staining
For immunostaining, ogNSCs were grown on cover slips
and transiently transfected with the T-83VP16 construct
for Oct4 stainings or untransfected for Pax6, Nestin and
Olig2 stainings. Cells were ﬁxed with 2.0% or 3.7% for-
maldehyde in phosphate-buffered salie (PBS) and
permeabilized in PBS containing 0.2% Triton X-100.
The Oct4 staining was performed using a goat primary
antibody against the murine Oct4 (goat; 1:1000, Santa
Cruz) and a secondary anti-goat antibody coupled to
Alexa Fluor 647 (1:2000, Molecular Probes). The neural
stem cell markers Pax6 (rabbit; 1:1000, Millipore), Nestin
(mouse monoclonal, Rat-401; 1:10, Developmental
Studies Hybridoma Bank, University of Iowa) and Olig2
(rabbit; 1:500, Millipore) were detected with secondary
antibodies conjugated to Alexa Fluor 488 (Molecular
Probes). The antibodies were diluted in PBS containing
0.02% Tween 20 and 2% bovine serum albumin (BSA).
Cells were counterstained with DAPI and mounted in
Vectashield (Vector Laboratories). Images were acquired
with a Zeiss Axioplan 2 ﬂuorescence microscope equipped
with a Plan-NEOFLUAR 40 /1.3 oil objective (Zeiss).
Cell culture, transfection and ﬂuorescence-activated cell
sorting
HEK293T cells (18) were cultured in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 50mg/ml
gentamicin and 10% fetal bovine serum (FBS).
For expression of fusion proteins, HEK293T cells were
transfected with polyethylenimine (Sigma). ogESCs were
cultured as described (19). ogNCSs were cultured in
N2B27 medium supplemented with 20ng/ml FGF-2
and EGF. NSCs and ESCs were transfected using
Lipofectamin 2000 (Invitrogen) according to the manufac-
turer’s instructions and sorted with a ﬂuorescence-
activated cell sorting (FACS) Aria II instrument (Becton
Dickinson).
Generation of transgenic cell lines
ogESCs were generated by transfecting wt J1 ESCs (20)
with the poct4-GFP reporter construct and repeated
sorting for eGFP expression. Finally, single cell sorting
was used to obtain a clonal transgenic cell line.
Derivation of NSCs from ESCs
ogESCs were differentiated into ogNSCs as previously
described (21–23). In brief, 3.5 10
5 cells were plated in
a2 5 c m
2 culture ﬂask with N2B27 medium containing
1000U/ml of LIF (ESGRO, Millipore). The next day
the medium was exchanged against N2B27 without LIF
to initiate differentiation into the neural lineage. After 7
days cells were plated in Euromed-N (Euroclone)
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After 5 days, neurospheres were collected and plated in
gelatin-coated ﬂasks in N2B27 medium containing 20ng/
ml EGF and FGF2 to allow outgrowth of NSCs.
Treatment of ogNSCs with epigenetic inhibitors
VPA sodium salt (Sigma-Aldrich) was dissolved in PBS at
a concentration of 250mM and sterile ﬁltered. 5-aza-20-
deoxycytidine (Sigma-Aldrich) was dissolved in PBS at a
concentration of 30mM. Trichostatin A (TSA; Sigma-
Aldrich) was dissolved in dimethyl sulfoxide (DMSO)
at a concentration of 5mM. Cells were transfected with
the T-83 construct as described above. Medium was
changed after 12 h against medium containing dilutions
of the respective inhibitor or combination thereof as
indicated in Figure 4 and respective legend. Cells
were cultured for additional 36 h followed by FACS and
quantitative real-time-polymerase chain reaction
(qRT-PCR).
In vitro methylation and reporter gene assay
In vitro methylation of poct4-GFP was performed using
M.SssI (New England Biolabs). Forty-ﬁve units of enzyme
were incubated with 45mg of plasmid DNA in the presence
of 160mM SAM overnight. After 3 h of incubation, fresh
SAM (160mM) was added to ensure complete methyla-
tion. Methylation status of the plasmid after invitro methy-
lation was tested by digestion with MspI and HpaII
(Fermentas). For the reporter gene assay HEK293T cells
were plated in six-well plates and grown to 70% conﬂu-
ence. Subsequently, cells were co-transfected with the
reporter plasmid and the respective dTALE construct.
Forty-eight hours after transfection cells were lysed in
PBS containing 0.5% NP40 and mammalian protease in-
hibitors. The lysate was cleared by centrifugation and
eGFP and mCherry ﬂuorescence was measured with a
Tecan Inﬁnite M1000 plate reader.
RNA Isolation, cDNA synthesis and qRT-PCR
Isolation of RNA and reverse transcription was carried
out as described previously (19). Real-time PCR analysis
was performed on the 7500 Fast Real-Time PCR System
(Applied Biosystems) at standard reaction conditions
using either the TaqMan Gene Expression Master Mix
(Applied Biosystems) or the Power SYBR Green
PCR Master Mix (Applied Biosystems). The following
TaqMan Gene expression assays were used:
gapdh (Assay ID: Mm99999915_g1), oct4 (Assay ID:
Mm00658129_gH) and nanog (Assay ID: Mm01617
761_g1). Primer sequences for SYBR Green PCRs:
gapdh (For 50catggccttccgtgttccta 30 Rev 50cttcaccaccttctt
gatgtcatc 30); tet1 (for 50ccaggaagaggcgactacgtt 30 Rev 50
ttagtgttgtgtgaacctgatttattgt 30) and hnf4a (for 50
caagaggtccatggtgtttaagg 30, Rev 50 cggctcatctccgctagct
30). Relative mRNA levels were normalized to gapdh
and calculated with the comparative CT Method (
CT
Method).
In vitro DNA-binding assays
In vitro DNA-binding assays were performed as described
previously (24,25) with the following modiﬁcations. Two
differentially ﬂuorescently labeled DNA substrates corres-
ponding to position   39 to+18 (A) and  88 to  31 (B)
relative to the TSS of the oct4 promoter (Figure 3) were
used in direct competition. Substrates were prepared
by annealing 50 ATTO550 or ATTO647N labeled
lower strand with the respective unlabeled upper strand
oligonucleotide. For competition assays, 200-nM
ATTO647N-labeled substrate A and ATTO550-labeled
substrate B were added and incubated at room tempera-
ture (RT) for 1h with constant mixing. Fluorescence
intensities were measured with a Tecan Inﬁnite M1000
plate reader using the following excitation/emission
wavelengths: 490±10nm/511±10nm for eGFP,
550±15nm/580±15nm for ATTO550 and
650±10nm / 670±10nm for ATTO647N. The measure-
ments were normalized using standard curves from
puriﬁed eGFP and ATTO-dye-labeled oligonucleotides.
Moreover, a control set of each substrate with distinct
ﬂuorophores was used for normalization.
Fluorescence polarization measurements
DNA afﬁnity was determined by ﬂuorescence polarization
measurements. eGFP-dTALE fusion proteins were
puriﬁed as described above and eluted from the
Sepharose beads by addition of 250mM imidazol.
Different concentrations of GFP-dTALE fusion proteins
were incubated with their speciﬁc ATTO647N-labeled
substrates (1nM). After incubation for 30min, at RT
ﬂuorescence polarization was measured with a Tecan
Inﬁnite M1000 plate reader using 635nm for excitation
and 670±10nm for emission. The data of ﬂuorescence
polarization over protein concentration were ﬁtted with
y ¼
ymax x
Kd+x using gnuplot (http://www.gnuplot.info).
DNA methylation analysis
For the analysis of DNA methylation levels at the oct4
promoter genomic DNA was isolated using the
NucleoSpin Triprep Kit (Macherey-Nagel). Bisulﬁte treat-
ment was performed using the EZ DNA Methylation-
Gold
TM Kit (Zymo Research Corporation) according to
the manufacturer’s protocol. Subsequently, the oct4
promoter sequence was ampliﬁed in a semi-nested PCR
using the primers:
F1: 50-ATGGGTTGAAATATTGGGTTTATTTA-30
F2: 50-GTAAGAATTGAGGAGTGGTTTTAG-30
R1: 50ACCCTCTAACCTTAACCTCTAAC 30
R2=R1 with 50biotin
The biotinylated PCR products of the second PCR were
analyzed by pyrosequencing (Varionostic GmbH, Ulm,
Germany). The pyrosequencing covered ﬁve CpG sites
of which the average methylation level was calculated.
DNA methylation levels of major satellite repeats and
H19 promoter was performed as previously described (25).
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Design and construction of ﬁve dTALEs targeting the
murine oct4 promoter
We generated ﬁve dTALEs each targeting a distinct 19-bp
sequence of the murine pluripotency gene oct4 to test
whether the position of the target sequence inﬂuences
the efﬁciency of dTALE-mediated promoter activation.
These ﬁve dTALEs targeted sequences upstream or down-
stream of the Sp1/Sp3/hormone responsive element
(HRE) box (Figure 1A, Supplementary Figure S1).
DNA-binding TALE repeat arrays were generated
by Golden Gate cloning as described previously (6) and
transferred to mammalian expression vectors by Gateway
recombination (Supplementary Figure S1A). To monitor
transfection efﬁciency and expression levels, mCherry (26)
was fused to the N-terminus of the dTALEs.
Furthermore, we replaced the transcriptional activation
domain (AD) of the Xanthomonas wild-type TALE
protein (wtdTALEs) with the VP16 AD from the herpes
simplex virus (VP16dTALEs) and compared the activity
of these two distinct dTALE architectures.
dTALEs targeting distinct sites in the oct4 promoter have
similar afﬁnities in vitro but differ strongly in their in vivo
performance as transcriptional activators
The activity of the different dTALEs was ﬁrst analyzed in
a transient reporter gene assay. HEK293T cells were
co-transfected with an oct4 promoter-driven eGFP
reporter (poct4-eGFP) and a constitutively expressed
dTALE construct. Expression was analyzed by ﬂuores-
cence measurement 48 h after transfection. Notably, the
VP16dTALEs activated the oct4 promoter to signiﬁcantly
higher levels than the corresponding wtdTALEs (Figure
1C), despite the fact that the latter were expressed at
slightly higher levels (Supplementary Figure S2). The
most distal dTALE (T-83) yielded the strongest transcrip-
tional activation with both, the wtdTALE and
VP16dTALE architecture (Figure 1B and C). To test
whether the variable efﬁciency of the dTALEs with
distinct repeat arrays is caused by the location of the
target sites within the promoter, we replaced base pairs
 31 to  102 of the oct4 reporter construct which
contain the target sites of four of the ﬁve dTALEs, with
a shorter sequence containing one dTALE target site only.
The resulting four reporter constructs have the respective
dTALE target site at the same position (Figure 2A).
Transcriptional activation of these four mutated reporter
constructs by the corresponding VP16dTALEs was
greatly reduced as compared to the activation level of
the wild-type oct4 reporter. Three of the four
VP16dTALEs induced similar eGFP expression levels
(Figure 2B) while T-60 exhibited a slightly stronger acti-
vation in the mutated promoter. The enhanced activity of
T-60 is possibly due to the overlap of its target site with
the SP1 site in the wild-type promoter, which also results
in a relatively higher background in cells transfected only
with the mutated reporter construct containing the T-60
binding site (Figure 2C). The dTALEs used in this study
were designed to target different sequences within the
promoter region of oct4. The distinct RVD compositions
of these dTALE repeat arrays might result in different
binding afﬁnity, causing the observed difference in tran-
scriptional activation. We therefore determined the
afﬁnity and speciﬁcity of our dTALEs in vitro using
ﬂuorescently labeled DNA substrates and eGFP–dTALE
fusion proteins. We found speciﬁc binding of all ﬁve
dTALEs to their respective DNA substrates (Figure 3A
and B). Dissociation constants were determined by ﬂuor-
escence polarization and all dTALEs tested yielded
afﬁnities for their speciﬁc substrates, with Kd values in
the low nanomolar to high picomolar range (Figure 3C).
Notably, the dTALE T-83, which was the strongest tran-
scriptional activator in vivo, had a comparably low afﬁnity
in vitro. Together, these data strongly suggest that the
observed variations in dTALE-mediated activation of
the oct4 promoter are not due to inherent differences in
their binding afﬁnity.
dTALEs activate methylated reporter plasmids
In addition to positional effects, we tested whether the
epigenetic state of the promoter might inﬂuence the
efﬁciency of dTALE-mediated transcriptional activation.
We methylated the poct4-GFP plasmid in vitro
(Supplementary Figure S3A) and determined its indu-
cibility by dTALEs. All dTALEs induced eGFP expres-
sion from the methylated oct4 promoter, yet to lower
levels as compared to the unmethylated reporter
(Figure 1D). Notably, the relative differences in the
activity of the highly potent T-83 and the other dTALEs
were up to 25-fold and thus more pronounced with the
methylated as compared to the unmethylated reporter
construct (Figure 1D). These results indicate that
dTALEs can activate heavily methylated promoter
sequences, albeit to a reduced extent, and suggest that
the lack of correlation between in vitro binding afﬁnity
and in vivo activity of dTALES may reﬂect their different
ability to overcome other repressive epigenetic marks at
the target locus.
dTALEs hyperactivate endogenous oct4 expression in
embryonic stem cells
To test the ability of dTALEs to activate the endogenous
oct4 gene we generated mouse embryonic stem cells
(ESCs) stably carrying the poct4-GFP reporter construct
(ogESCs). ogESCs were tested with T-83 fused to the
VP16 AD (VP16 T83), the most efﬁcient dTALE, and
compared with mCherry control vector. Transfected
mCherry-positive cells were selected using FACS and
total RNA was isolated followed by reverse transcription
and qRT-PCR. FACS analysis showed that ogESCs trans-
fected with the VP16 T-83 had a 3–4-fold higher mean
eGFP ﬂuorescence intensity compared to control trans-
fected cells (Supplementary Figure S4A). Transcription
of the endogenous oct4 was induced about 2-fold as
determined by qRT-PCR (Supplementary Figure S4B).
The relatively low induction rate is likely due to the high
basal level of oct4 transcription in ESCs and the negative
feedback of Oct4 on its own promoter (27).
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To test whether dTALEs can also activate a transcription-
ally silent endogenous oct4 promoter, we differentiated
ogESCs into NSCs. During this differentiation process
the oct4 locus is epigenetically silenced and NSCs no
longer express oct4 (28). Analysis by immunoﬂuorescence
showed that all cells were positive for the NSC markers
(21) Pax6, Nestin and Olig2 (Supplementary Figure S5),
indicating successful in vitro differentiation from ogESCs
to ogNSCs. The ogNSCs were transfected with the vector
encoding the dTALE VP16 T-83 or a control vector
encoding mCherry. Forty-eight hours after transfection
cells were analyzed by ﬂow cytometry. In contrast to the
experiments with ogESCs, the dTALE VP16 T-83
activated neither the transgenic poct4-eGFP reporter nor
the endogenous oct4 promoter in ogNSCs (Figure 4A and
B). This could be due to the different epigenetic states of
the oct4 promoter in ESCs and NSCs. Whereas the oct4
promoter in ESCs is active and apparently accessible to
dTALEs, oct4 is not expressed in NSCs and the promoter
A
B
CD
Figure 1. Activation of a transgenic oct4 reporter construct by dTALEs in HEK293T cells. (A) Schematic representation of the 102-bp fragment
upstream of the transcriptional start site (TSS) of the oct4 promoter, including the binding site of the Sp1/Sp3 transcription factors, the hormone
responsive element (HRE) and two CpG sites (open circles). oct4-speciﬁc dTALEs are depicted in correspondence of the location of their target
sequence and designated according to the distance between the 50 end of their target sequence and the TSS. (B) Fluorescence microscopy images of
HEK293T cells co-transfected with the poct4- GFP reporter construct and the T-83 dTALE constructs. Left panel shows cells transfected with the
T-83 dTALE fused to the wild-type AD (wt AD). Right panel shows cells transfected with the T-83 dTALE fused to the VP16 AD. Scale
bar=200mm. (C) Transcriptional activation of the unmethylated poct4-GFP reporter construct by oct4-speciﬁc dTALEs. eGFP expression was
normalized to cells co-transfected with a control plasmid encoding the ﬂuorescent protein mCherry (mCh) and poct4-GFP reporter construct.
(D) Transcriptional activation of the in vitro methylated poct4-GFP reporter construct by oct4-speciﬁc dTALEs. eGFP expression was normalized
to cells co-transfected with a control plasmid (mCh) and poct4-GFP reporter construct. To allow for a direct comparison of expression levels in
(C) and (D) the data observed on the methylated promoter were normalized to the mCherry values observed with the unmethylated promoter
(C). Error bars in (C) and (D) represent standard deviation from three independent experiments.
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Therefore, we envisaged that inhibiting the repressive epi-
genetic modiﬁers that prevent activation of the oct4
promoter in NSCs could allow dTALE-mediated activa-
tion of oct4. To test this hypothesis, we used the HDAC
inhibitors TSA (29) or VPA (30) as well as the DNA
methyltransferase (Dnmt) inhibitor 5-aza-2’-deoxycytidine
(5azadC) (31) to interfere with two major epigenetic mech-
anisms by which transcriptional silencing of genes is
achieved in mammals. Twelve hours after transfection
with VP16 T-83, ogNSCs were treated with the respective
inhibitor for additional 36 h. Treatment with 5azadC or
VPA but not TSA signiﬁcantly increased relative
eGFP expression in cells transfected with VP16 T-83
(Figure 4A and Supplementary Figure S6A–C).
Similarly, endogenous oct4 transcript levels were induced
up to 60% as compared to the levels in ogESCs. However,
a combination of 5azadC and VPA did not show additive
nor synergistic effects (Figure 4A and B). Treatment with
the inhibitors alone did not result in transcriptional acti-
vation of the reporter nor the endogenous oct4 gene
(Figure 4A and B), demonstrating that the observed acti-
vation was due to the synergistic action of the dTALE and
the inhibitors. Cells transfected with the dTALE VP16
T-83 and treated with VPA, 5azadC or combinations of
both showed not only increased oct4 transcript levels but
also Oct4 protein (Figure 4F). Moreover, treatment of
VP16 T-83 transfected cells with VPA, 5azadC or combin-
ations of both exhibited up-regulation of the Oct4 target
genes nanog and tet1 (Figure 4C and D) (32–34). By
contrast, genes that are not part of the Oct4 regulatory
network were not inﬂuenced by treatment with inhibitors
and/or expression of dTALE VP16 T-83 on transcript
(Supplementary Figure S7A).
As both, 5azadC and VPA, have been reported to
induce DNA demethylation (31,35) we investigated the
effects of these inhibitors on the DNA methylation levels
of the oct4 promoter. Interestingly, in all samples that
were treated with the inhibitors only and/or transfected
with the control plasmid no change in DNA methylation
levels was observed. However, expression of the dTALE
VP16 T-83 together with VPA and/or 5azadC treatment
caused a reduction of DNA methylation at the oct4
promoter by  30% (Figure 4E). Treatment with inhibi-
tors alone or in combination with the dTALEs did not
inﬂuence methylation levels at the h19 locus and major
satellite repeats, showing that the observed effect is
speciﬁc for the oct4 promoter (Supplementary Figure
S7B and S7C). These results suggest a synergistic effect
of dTALEs and epigenetic inhibitors in mammalian cells.
DISCUSSION
Variable efﬁciency of different dTALEs in
transcriptional activation
In eukaryotic cells, transcriptional activation involves the
concerted action of multiple factors recognizing target
sites at different positions of gene promoters. The possi-
bility to generate dTALEs that bind different sites within
the promoter of target genes opens new possibilities to
probe and optimize conditions for targeted transcriptional
activation. We designed a panel of dTALEs targeting
distinct sites in the murine oct4 promoter and compared
their performance in vitro and in vivo. Expression of
dTALE T-83 resulted in a 2-fold increase of the oct4
mRNA in ESCs. Previous studies reported a number
of dTALEs targeting distinct promoters (5–7,36,37).
However, none of these studies has systematically
investigated whether the relative position of a dTALE
target site within a promoter affects its functionality. We
engineered ﬁve dTALEs, each targeting a distinct 19-bp
sequence within the oct4 promoter. All dTALEs yielded
Kd values in the low nanomolar to high picomolar range
and were expressed at similar levels but differed largely in
their efﬁciency in vivo. Remarkably T-83, the dTALE with
one of the lowest binding afﬁnity, showed the highest
efﬁciency in oct4 promoter activation. Our data obtained
with recombinant oct4 promoter constructs showed that
deletions in the native oct4 promoter severely affected
A
BC
Figure 2. The location of a dTALE target sequence within the oct4
promoters can affect its functionality. (A) Schematic representation of
an oct4 promoter deletion construct in which base pairs  31 to  102
relative to the TSS were deleted and the target sequences of the four
dTALEs were inserted yielding the reporter constructs TB31, TB60,
TB68 and TB83. (B) Transcriptional activation of the reporter con-
structs TB31, TB60, TB68 and TB83 by corresponding dTALEs.
(C) Background activity of the mutated reporter constructs in cells
co-transfected with respective reporter and mCherry control.
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speciﬁc binding site is not sufﬁcient for efﬁcient activation
of transcription. These results suggest that the different
capacity of dTALEs to activate transcription is less
determined by their intrinsic DNA-binding properties
but rather by their interactions at target promoters.
Studies with the viral transactivator VP16 had previously
indicated position-dependent interactions of the VP16 ac-
tivation domain, possibly with basal transcription factors
(38). Therefore, it is likely that also dTALEs are involved
in complex interactions at the promoter of target genes
that may either hinder or promote transcriptional
activation.
As multiple cis- and trans-acting factors and epigenetic
modiﬁcations are involved in the regulation of promoter
activity, it will be difﬁcult to predict the efﬁciency of a
dTALE in silico. Hence, it seems important to construct
and test multiple dTALEs for a given target promoter to
obtain the most effective transcriptional activator. In the
past, the assembly of genes that encode custom-designed
repeat arrays was challenging and thus construction of
multiple dTALEs targeting one promoter was not a real-
istic task. However, this is no longer a bottleneck since the
recently established hierarchical ligation-based ‘Golden
Gate’ cloning approaches facilitate rapid generation of
genes encoding TALE repeat arrays (5,6,9,36,37,39,40).
Another potential bottleneck in the selection of efﬁcient
dTALEs is the analysis of promoter activation by
RT-PCR or comparable assays. By contrast, promoter–
reporter fusions constructs facilitate rapid quantitative
comparison of multiple dTALEs but may not adequately
reﬂect the transcriptional regulation of the corresponding
endogenous genes. In this context, it should be noted that
the dTALE (T-83), performing best on plasmid reporters,
also most efﬁciently activated the chromosomal oct4
promoter (Supplementary Figure S6E). Thus, promoter–
reporter fusions may greatly facilitate the screening of dif-
ferent dTALE repeat arrays and experimental conditions
that can then be veriﬁed and optimized in a second step by
monitoring transcription of the endogenous genes.
Transcriptional activation by dTALEs is facilitated
by epigenetic inhibitors
In a recent study, dTALEs were shown to activate an
episomal oct4 reporter but not the endogenous oct4
promoter (5). Similarly, we observed a lack of dTALE-
mediated oct4 activation in NSCs, where the promoter is
silent. In ESCs, however, where the oct4 promoter is
active, our dTALE clearly increased oct4 transcription,
suggesting that dTALE activity depends on the epigenetic
state of the promoter. These results are consistent with the
reported multistep inactivation of the oct4 promoter that
occurs during cellular differentiation after implantation
and involves H3K9 as well as DNA methylation. This
tight epigenetic control apparently safeguards against
A
B
C
Figure 3. (A)DNA-binding properties of oct4 eGFP-dTALE fusion proteins in vitro. Schematic representation of the 102-bp upstream of the
transcriptional start site (TSS) of the oct4 promoter, including the binding site of the Sp1/Sp3 transcription factors, the hormone responsive
element (HRE) and two CpG sites (open circles). oct4 eGFP–dTALE fusion proteins are depicted at the position of their target sequence and
numbered according to the distance between the 50 end of their target sequence and the TSS of the oct4 gene. Binding assays were performed using
ﬂuorescently labeled double-stranded DNA substrates corresponding to position  39 to +18 [substrate A (SA)] and  88 to  31 [substrate B (SB)]
relative to the TSS of the oct4 gene. Note that substrate A includes the targeting sequences of dTALEs T-11 and T-31 and substrate B includes the
targeting sequences of dTALEs T-60, T-68 and T-83. (B) DNA binding of eGFP-dTALE fusions to the speciﬁc substrate in competition with the
respective unspeciﬁc substrate. Shown are ﬂuorescent intensity ratios of bound labeled DNA substrate/eGFP-dTALE fusions. eGFP was used as
negative control. Values represent means and ±SEM from three independent experiments. (C) DNA afﬁnity measurements of the ﬁve dTALEs as
measured by ﬂuorescence polarization. Upper panel shows the data points acquired for each dTALE and the corresponding ﬁtted curves. The table
contains the Kd values for each dTALE calculated from the ﬁttings using gnuplot and the function fx ðÞ ¼ Ymax x
Kd+x .
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Figure 4. Activation of the endogenous oct4 gene in NSCs requires inhibition of repressive epigenetic mechanisms. (A) Relative eGFP intensities as
measured by ﬂow cytometry of mCherry-positive ogNSCs transfected with the VP16 T-83 dTALE construct (T-83). Cells transfected with control
plasmid (blue) or T-83 (red) were untreated or treated with TSA (30nM), VPA (620mM), 5azadC (10nM) or a combination of VPA (310mM) and
ﬁve azadC (5nM). (B) Relative levels of endogenous oct4 mRNA measured by quantitative real-time PCR of transfected, mCherry-positive ogNSCs
from (A) as well as untransfected ogNSCs and ogESCs as a reference. (C) DNA methylation levels of the oct4 promoter in samples from (A) and of
ogESCs as well as ogNSCs as reference. Percentage of methylation represents the average of ﬁve CpG sites in the proximal part of the oct4 promoter.
(D, E) Relative mRNA levels of tet1 and nanog as determined by quantitative real-time PCR of samples from (A) and of ogESCs as well as ogNSCs
as reference. (F) Fluorescence microscopy images of ogNSCs transfected with the T-83 construct in combination with 5azadC treatment (10nM) or
no drug. Samples were stained for Oct4 protein (A647) and counterstained with DAPI. mCherry channel shows cells transfected with T-83. eGFP
channel shows expression of the oct4 reporter transgene. Scale bar represents 25mm. For images of samples treated with the other inhibitors, see
Supplementary Figure S4. Error bars represent standard deviation from two to three independent experiments. Asterisks indicate samples where no
mRNA was detectable by quantitative real-time PCR.
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prevents uncontrolled proliferation and cancer (41–43).
We found that chemical inhibition of repressive epigen-
etic modiﬁers like Dnmts and HDACs enabled dTALE-
mediated transcriptional activation of silent oct4 in NSCs.
Interestingly, of the two HDAC inhibitors tested only
VPA but not TSA treatment allowed efﬁcient transcrip-
tional activation of oct4 by dTALEs. A similar difference
between the two inhibitors was previously reported for
cellular reprogramming and oct4 promoter activation
(44). One possible explanation for the different efﬁcacy
of the two inhibitors could be their different target
speciﬁcities (45). Interestingly, VPA was shown to specif-
ically affect the proximal region of the oct4 promoter (46)
where also the T-83 dTALE binds. This might also explain
why inhibitor treatment of cells transfected with T-31, the
dTALE with the next greatest activity in the reporter
assays, did not facilitate the activation of oct4 (Supple-
mentary Figure S6E).
Previous studies reported that high concentrations of
VPA and/or 5azadC induce demethylation and reactiva-
tion of silent genes (35,47,44,46,38). Under our experimen-
tal conditions, however, these inhibitors induced DNA
demethylation of the oct4 promoter only in combination
with dTALEs, indicating a synergistic effect. A possible
explanation could be that binding of the dTALE interferes
with maintenance of DNA methylation and, thus, in com-
bination with the epigenetic inhibitors leads to reduction
of methylation levels. Such a synergistic effect would be
consistent with the recent realization that DNA methyla-
tion is rather dynamic and functionally linked to other
epigenetic pathways (48). The synergy between low con-
centrations of epigenetic inhibitors and dTALEs suggests
that silent target genes could be activated without
genome-wide demethylation and thus avoid unwanted
side effects.
In summary, we demonstrated that combining dTALEs
with DNA methylation and/or HDAC inhibitors facili-
tates selective activation of the endogenous oct4
pluripotency gene. As in turn also Oct4 target genes are
reactivated, dTALEs could be used for reprogramming of
somatic cells to induced pluripotent stem cells (iPSCs).
It remains to be investigated whether single or combin-
ations of several dTALEs are more efﬁcient than present
reprogramming strategies involving the Oct4 protein itself.
However, in contrast to native transcription factors,
dTALEs can be speciﬁcally directed against single genes
or selected combinations of target genes and thereby allow
dissection of complex transcription networks to identify
key factors in biological processes like pluripotency and
differentiation. The combination with epigenetic inhibi-
tors may, in some cases, facilitate the activation of
tightly repressed genes and further expand the utility of
dTALEs in basic and applied biosciences.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Figures 1–7.
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